PROK

ProKidney Corp.

Healthcare
Biotechnology
$605M market cap

Forecast run · Sep 14, 2026Upside rank 1104 of 3,136

Model Signal

ForecastQ Daily Probabilities

43.0%

53.3%

30.4%

Analyst Consensus

Recommendation2.38/5 Buy

Last price$1.80

Price target$4.67

Implied move+159.4%

Analysts8

ForecastQ Portfolios

PROK is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.